Patent application number | Description | Published |
20100310649 | SOLID LIPID MICROCAPSULES CONTAINING GROWTH HORMONE INNER CORE MICROPARTICLES - The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter. | 12-09-2010 |
20140105858 | IFN-BETA COMPOSITIONS, PREPARATION METHODS AND USES THEREOF - The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26,000 and 40,000 g/mol, grafted with alpha-tocopherol substituents, the average molar grafting ratio being 4.5-5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time. | 04-17-2014 |
20140127303 | SUSTAINED-RELEASE COMPOSITION CONTAINING PEPTIDES AS ACTIVE INGREDIENT - The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium. | 05-08-2014 |
20140128422 | NEW THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT - A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place. | 05-08-2014 |
Patent application number | Description | Published |
20100239529 | PEG-Interferon-Beta Formulations - The invention relates to a liquid pharmaceutical composition comprising a pegylated IFN-β (PEG-IFN-β), an excipient, a surfactant and a buffer wherein said excipient is a polyol, wherein said surfactant is a non-ionic surfactant and wherein said buffer is a sodium acetate buffer. | 09-23-2010 |
20100239580 | TACI-IMMUNOGLOBULIN FUSION PROTEINS FOR TREATMENT OF OPTIC NEURITIS - The invention relates to TACI-Immunoglobulin fusion proteins for the treatment of optic neuritis. | 09-23-2010 |
20100261649 | LH LIQUID FORMULATIONS - The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration. | 10-14-2010 |
20120321714 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF - The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound. | 12-20-2012 |
20140056977 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF - The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound. | 02-27-2014 |